Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

ASH 2018

All Publications

Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent Who Are Lenalidomide and HMA Naive

Clinical Imetelstat: MDS Imetelstat

Steemsma D, et al.

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Clinical Imetelstat: MF Imetelstat

Mascarenhas J, et al.

[facetwp facet="publication_load_more"]